Astellas Pharma gets FDA fast track status for ASP036 to treat primary mitochondrial myopathies

This article was originally published here

PMM is a complex mitochondrial disease in which genetic mutations mainly impair the function of mitochondria that may result in reduced muscle function, reduced endurance to exercise, increased

The post Astellas Pharma gets FDA fast track status for ASP036 to treat primary mitochondrial myopathies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply